Zobrazeno 1 - 6 of 6 pro vyhledávání: '"Giovanna Forero"'
1
Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder
Autor: Suresh Durgam, David V. Sheehan, Giovanna Forero, Xiongwen Tang, Rene Nunez, Carl Gommoll, Maju Mathews
Publikováno v: The Journal of Clinical Psychiatry. 77:1687-1694
Objective To evaluate the efficacy, safety, and tolerability of vilazodone as an acute treatment for generalized anxiety disorder (GAD). Vilazodone is a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist approved for the treat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01080a10db9f96c741506d0a8fdb801a
https://doi.org/10.4088/jcp.15m09885
Zobrazit plný text záznamu
2
Vilazodone in patients with generalized anxiety disorder
Autor: Angelo Sambunaris, Suresh Durgam, Xiongwen Tang, Giovanna Forero, Carl Gommoll, Maju Mathews, Rene Nunez
Publikováno v: International Clinical Psychopharmacology
Vilazodone is a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist that is approved for treatment of major depressive disorder in adults in the USA and Mexico. The efficacy, safety, and tolerability of vilazodone for general
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d4d8790211580585dd46be80230442f
https://doi.org/10.1097/yic.0000000000000096
Zobrazit plný text záznamu
3
A DOUBLE‐BLIND, RANDOMIZED, PLACEBO‐CONTROLLED, FIXED‐DOSE PHASE III STUDY OF VILAZODONE IN PATIENTS WITH GENERALIZED ANXIETY DISORDER
Autor: Suresh Durgam, Michael E. Thase, Maju Mathews, Xiongwen Tang, Carl Gommoll, Rene Nunez, Giovanna Forero
Publikováno v: Depression and Anxiety
Background Vilazodone, a selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist, is approved for treating major depressive disorder in adults. This study (NCT01629966 ClinicalTrials.gov) evaluated the efficacy and safety of vilazo
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bbe5effb678a947dbb92ef6ba06edce
https://doi.org/10.1002/da.22365
Zobrazit plný text záznamu
4
Safety and Tolerability of Levomilnacipran ER in Major Depressive Disorder: Results from an Open-Label, 48-Week Extension Study
Autor: William M. Greenberg, Changzheng Chen, Giovanna Forero, Carl Gommoll, Rajnish Mago
Publikováno v: Clinical Drug Investigation
Background Levomilnacipran (1S, 2R-milnacipran) is a potent and selective serotonin (5-HT) and norepinephrine (noradrenaline) reuptake inhibitor approved for the treatment of major depressive disorder in adults. Objective The objective of this study
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::288b3a751022933e61906cc0aa0fc6ff
http://europepmc.org/articles/PMC3775192
Zobrazit plný text záznamu
5
A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder
Autor: Thomas, Shiovitz, William M, Greenberg, Changzheng, Chen, Giovanna, Forero, Carl P, Gommoll
Publikováno v: Innovations in clinical neuroscience. 11(1-2)
Major depressive disorder is often chronic, with relapse and recurrence common. Levomilnacipran extended-release is a potent and selective serotonin and reuptake inhibitor approved in the United States for treatment of major depressive disorder in ad
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::8792f9fb078fed066961db9fcc7628bc
https://pubmed.ncbi.nlm.nih.gov/24653937
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje